Gilead Buying Liver Disease Drugmaker CymaBay For $4.3B
Gilead Sciences Inc. said Monday that it has agreed to purchase liver disease-focused clinical-stage biopharmaceutical company CymaBay Therapeutics Inc. for $4.3 billion in cash....To view the full article, register now.
Already a subscriber? Click here to view full article